Evidence map›Paper›PMID 39678908›Full record

ArticleJournal of thoracic disease2024

Neoadjuvant immunology therapy in patients with non-small cell lung cancer and chronic obstructive pulmonary disease.

Qing Chang, Jiaqi Li, Yan Zhu, Huiping Qiang, Haijiao Lu, Yinchen Shen, Shuyuan Wang, Jialin Qian, Tianqing Chu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qing Chang *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiaqi Li *Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yan ZhuDepartment of Pulmonary Function, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Huiping QiangDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Haijiao LuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yinchen ShenDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Shuyuan WangDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jialin QianDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Tianqing ChuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: For patients with early non-small cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD), the efficacy and safety of immunotherapy are still unclear. This study was designed to investigate the effect and safety of neoadjuvant immunotherapy for patients with resectable NSCLC including those with coexisting COPD and the effect on patients' lung function. Methods: Data of patients with resectable NSCLC who received neoadjuvant immunotherapy at the Shanghai Chest Hospital were retrospectively analyzed. Results: A total of 57 patients were enrolled and 18 of those were with coexisting COPD. For COPD patients, the objective response rate (ORR), major pathological response (MPR), and pathological complete response (pCR) were 44.4%, 55.6%, and 38.9%, respectively, which were not statistically different from those of non-COPD patients. The 2-year event-free survival (EFS) and overall survival (OS) rates were 73.7% and 88.5%, respectively, which were lower than those of patients without COPD, but the difference was not statistically significant. After neoadjuvant immunotherapy, the ratio of forced expiratory volume in 1 second (FEV1), the ratio of FEV1 to the predicted value (FEV1%pred), forced vital capacity (FVC), and the ratio of FVC to the predicted value (FVC%pred) all improved, however, carbon monoxide diffusing capacity (DLCO) and DLCO adjusted by hemoglobin (DLCOc) were lower. For patients with COPD, only FEV1 improved after immunotherapy. Conclusions: For resectable NSCLC patients with COPD, neoadjuvant immunotherapy could achieve better pathological response, survival benefit and improve patients' lung function.

Indexed as

chronic obstructive pulmonary disease (COPD)immunotherapymajor pathological response (MPR)neoadjuvant therapyNon-small cell lung cancer (NSCLC)

Identifiers

PMID39678908
PMCPMC11635264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.